Does MSM Work? What the Evidence Really Shows
Educational summary — not medical advice. MSM is studied as a low-risk adjunct for joint comfort and exercise recovery, with modest, mixed evidence — not a treatment. If you have significant or worsening joint pain, see a clinician. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
MSM's evidence is modest and mixed, and it leans toward physical function more than pain. Two small knee-osteoarthritis pilots improved function — Kim 2006 (6 g/day, WOMAC pain and function) and Debbi 2011 (~3.4 g/day) — but in Debbi, pain did NOT reach significance (p=0.08); the significant gains were in function and total WOMAC. For exercise recovery, Withee 2017 found pain down clinically but not statistically, with no effect on damage or oxidative markers, and Kalman 2012 (n=8) saw trends only. MSM is GRAS and well tolerated to ~4 g/day (Butawan 2017).
Knee osteoarthritis: function yes, pain uncertain
The strongest case for MSM is in knee osteoarthritis (OA), and even there it's two small, short pilot trials pointing more clearly at physical function than at pain. Kim 2006 gave 6 g/day and reported improvement in WOMAC pain and physical function — but published significance rather than exact effect sizes, so the magnitude isn't quantifiable from the trial. Debbi 2011 gave ~3.4 g/day and found significant improvement in physical function and total WOMAC — while pain did not reach statistical significance (p=0.08) and stiffness was not significant either. Read together, the honest claim is a possible modest improvement in joint function, with the pain benefit genuinely uncertain.
What the trials show — and where they stop
Four small human trials carry most of the weight. Read them for what they actually measured, not the headline:
| Study | Design / dose | Finding | The honest limit |
|---|---|---|---|
| Kim 2006 PMID 16309928 | Knee-OA pilot RCT; 6 g/day | Improved WOMAC pain and physical function vs placebo (significance reported) | Small, short pilot; exact effect sizes not published — treat as a signal, not a magnitude |
| Debbi 2011 PMID 21708034 | Knee-OA RCT; ~3.4 g/day | Physical function & total WOMAC significant; pain NOT significant (p=0.08); stiffness NS | The pain benefit missed significance — the reliable improvement was in function |
| Withee 2017 PMID 28736511 | Half-marathon RCT; 3 g/day OptiMSM | Post-exercise pain down clinically but not statistically; no effect on muscle-damage or oxidative markers | Doesn't measurably reduce exercise-induced muscle damage or oxidative stress |
| Kalman 2012 PMID 23013531 | Exercise pilot; n=8; 1.5 & 3 g/day | Soreness/fatigue trends (not significant); some antioxidant-marker shifts | Tiny pilot (8 people) — hypothesis-generating, not confirmatory |
Read together: the OA pilots support a modest improvement in physical function, with the pain signal present in one trial (Kim) but not significant in the other (Debbi, p=0.08). The exercise-recovery work is weaker — a small, clinically-but-not-statistically meaningful dip in soreness and, importantly, no measurable effect on muscle damage or oxidative stress (Withee 2017). These are small studies (roughly 50 people or fewer), so treat MSM as a low-risk option with modest signals, not a proven therapy.
The claim to be careful with It's tempting to say MSM "significantly reduces joint pain" and "cuts exercise oxidative stress." Neither is well supported: the more rigorous OA trial found pain did not reach significance (Debbi 2011, p=0.08), and the half-marathon trial found no effect on oxidative-stress or muscle-damage markers (Withee 2017). The defensible claims are narrower: a possible modest gain in physical function in knee OA, and perhaps a small subjective dip in soreness.
Who it's most reasonable for
- People with knee OA who want a low-risk add-on — where the modest function signal is clearest (Kim 2006; Debbi 2011), with expectations set to "function, maybe; pain, uncertain."
- As an adjunct, not a replacement — alongside exercise, weight management, and whatever your clinician recommends; MSM is inexpensive and well tolerated, which is much of its appeal.
- Value-minded buyers — since the molecule is identical across brands and the evidence is modest, there's no reason to overpay: buy the cheapest grams that hit your dose.
Set expectations honestly, and see a clinician if you have significant, worsening, or red-flag joint symptoms — MSM is a modest adjunct, not a treatment for a joint problem that needs medical evaluation.
Frequently asked questions
Does MSM work for knee osteoarthritis?
Modestly and mixed, leaning to function over pain. Kim 2006 (6 g/day) improved WOMAC pain and function; Debbi 2011 (~3.4 g/day) improved function and total WOMAC but pain wasn't significant (p=0.08). Small, short pilots.
Does it help exercise recovery and soreness?
Weakly. Withee 2017 found post-exercise pain down clinically but not statistically, with no effect on muscle-damage or oxidative markers; Kalman 2012 (n=8) saw trends only. A small subjective edge at most.
Is MSM safe?
Good profile: GRAS and well tolerated to ~4 g/day, with mild GI effects or occasional headache (Butawan 2017). Trials are small and short, so check with a clinician if pregnant, on medication, or managing a condition.
How strong is the overall evidence?
Limited — few, small (~50 or fewer), short trials with mixed results: function improved, pain inconsistent, recovery effects trend-level. A low-risk option with modest signals, not a proven treatment.
Related
- MSM: what it is & who it's for
- MSM dosage guide — the 1.5–6 g/day trial range + a checker
- MSM cost per gram — why the identical molecule means you shouldn't overpay
- Best MSM — ranked by cost per gram of MSM
Sources
- Kim LS, et al. "Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial." Osteoarthritis Cartilage. 2006. PMID: 16309928
- Debbi EM, et al. "Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study." BMC Complement Altern Med. 2011. PMID: 21708034 (function & total WOMAC significant; pain NS, p=0.08).
- Withee ED, et al. "Effects of methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial." J Int Soc Sports Nutr. 2017. PMID: 28736511 (pain down clinically not statistically; no effect on damage/oxidative markers).
- Kalman DS, et al. "Influence of methylsulfonylmethane on markers of exercise recovery and performance in healthy men: a pilot study." J Int Soc Sports Nutr. 2012. PMID: 23013531 (n=8 pilot; trends).
- Butawan M, et al. "Methylsulfonylmethane: applications and safety of a novel dietary supplement." Nutrients. 2017. PMID: 28300758 (GRAS; well tolerated ~4 g/day).